Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HO/03/03 in Diabetic Foot Ulcers (Truheal)
NCT00926068Phase 2Unknown
- Sponsor
- HealOr Ltd.
- Start
- Feb 2010
- Primary completion
- Aug 2013
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing HO/03/03 10µg with Placebo (2 arms). Primary endpoint: Complete ulcer closure at 14 weeks. Status: unknown.
02
Drugs
HO/03/03
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT00926068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00926068.